South Korea’s Daewoong Pharmaceutical will Collaborate with Indonesia’s National Institute of Health and Technology Development (NIHRD) on the development of COVID-19 treatments
Highlights: Daewoong Infion, the Indonesian subsidiary of South Korea’s Daewoong Pharmaceutical, has signed a memorandum of understanding (MoU) with Indonesia’s National Institute of Health and Technology Development (NIHRD) to collaborate on the development of COVID-19 treatments. The two organizations will work together to identify and develop potential treatments for COVID-19, as well as to conduct clinical trials and obtain regulatory approval for any new treatments that are developed. The partnership aims to accelerate the development of effective COVID-19 treatments to help combat the pandemic.
Link to Original Article